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ABSTRACT
Delivery is a very important concern for therapeutic
applications of siRNA. In this study, we have used
chitosan-coated poly(isobutylcyanoacrylate) nano-
particles to deliver siRNA with a complementary
sequence to the fusion oncogene ret/PTC1. By
screening the mRNA junction we have selected a
potent siRNA sequence able to inhibit this onco-
gene in a model of Papillary Thyroid Carcinoma
cells. This siRNA sequence has then been validated
by a shRNA approach using the same sequence.
Furthermore, the high ret/PTC1 inhibition has trig-
gered a phenotypic reversion of the transformed
cells. We have designed well-defined chitosan
decorated nanoparticles and succeeded to reduce
their size. They have allowed to protect ret/PTC1
siRNA from in vivo degradation and leading to
significant tumour growth inhibition after intra-
tumoral administration.
INTRODUCTION
As with all nucleic acids, in vivo application of interfering
strategy via siRNA or shRNA raises many challenges,
such as transfection and tissue targeting (1,2). In fact,
these molecules have excessive hydrophilic properties, and
a poor in vivo stability. One pharmacological strategy is
therefore to use vectors. Viral vectors are still the most
powerful tool for gene transfection, because of their
high eﬃciency in transduction, some of them being
able to infect non-dividing cells. However, the death of
J. Gelsinger in 1999, 4 days after an injection of
adenovirus for a gene therapy trial (3) increased the
attraction for the non-viral vectors approach. Non-viral
vectors, although less eﬃcient than viruses for gene
delivery, oﬀer however several advantages (4). They are
particularly simple to use and can easily be produced
at a large scale, and at a relatively low cost. It is easy to
control their quality and they generate little or no speciﬁc
immune responses. For these reasons, non-viral vectors
have already become a powerful and popular research tool
to elucidate gene structure, regulation and function.
Various types of synthetic vectors such as cationic lipids
and polymers have been developed for gene transfer and
have proved eﬃcient for the transfections. In these poly-
electrolyte complexes, DNA is tightly packed, thus
preventing the degradation by nucleases (5–7). These
positively charged vectors are mainly cell internalized by
non-speciﬁc electrostatic interactions (8). For example,
chitosan, a positively charged polysaccharide contain-
ing non-acetylated beta-linked D-glucosamine residues has
been intensively investigated as a nucleic acid delivery
system. This polysaccharide extracted from chitine pos-
sesses a lot of qualities for DNA delivery such as the low
cost of the vector, its easy to use and the biocompatibility.
Since MacLaughlin’s experiment (9), chitosan entered in
the list of non-viral vectors. It has already been usefully
utilized for the in vivo and in vivo delivery of siRNA as
chitosan-based nanoparticles (10–13).
In the present study, we have used a new core-shell type
of nanoparticles, where the core consisted of the bio-
degradable poly(isobutylcyanoacrylate) polymer and the
shell of chitosan. These positively charged nanoparticles
have never been used before as drug carriers for in vivo
studies and the optimization of their synthesis allowed
to dramatically reduce their diameter. The experimental
treatment of papillary thyroid carcinoma by siRNA
loaded onto those chitosan-coated poly(isobutylcyano-
acrylate) nanoparticles was chosen here to exemplify the
usefulness of this delivery approach.
Thyroid is the most frequently aﬀected organ by endo-
crine cancers and represents 1% of all malignancies.
Irradiation is the main traumatism responsible for thyroid
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thyroid cancers after the Chernobyl catastrophe (14,15).
Thyroid cancers are observed in 57–87% of the malign
tumours 5–8 years after the exposure and in 49–65%
7–11 years after (16). It is the eighth most common
malignancy of woman cancer (17). Among all thyroid
cancers, papillary thyroid carcinomas (PTCs), derived
from follicular cells, are the most frequent, especially in
radiation-associated thyroid carcinomas (18). It is due to
a chromosomal rearrangement involving the ret receptor
gene. ret encodes for a membrane tyrosine kinase receptor
for a glial cell-derived neurotropic growth factor, and has
a role in the regulation of growth, survival, diﬀerentiation
and migration. ret is not normally expressed in thyroid
follicular cells. Rearrangement involving the chromosome
10, between ret, and an ubiquitous gene leads to the
abnormal expression of a chimeric constitutively activated
ret protein in follicular cells. In the main cases it leads to
the juxtaposition of the ret tyrosine kinase domain with
H4 gene (ret/PTC1 type) or with ELE1 (ret/PTC3 type)
(19,20). These rearrangements are consistently found in
radiation-associated thyroid carcinomas (18) and are
very frequent in clinically silent small thyroid tumours.
Ret/PTC1 (the H4-ret fusion) is one of the most prevalent
variants, especially in PTCs that occurred in children
after the nuclear fallout in the Chernobyl area (14,21) and
after external irradiation to medical treatment (18,22).
The spatial proximity of ret gene with H4 during
thyrocyte interphase can explain the ret/PTC1 formation
(23). Despite a relatively low prevalence in adult PTCs,
ret/PTC1 appears to be very dominant in pediatric
PTCs (24).
The treatment of these cancers typically involves radio-
active iodine, surgical resection, and lifelong levothyroxine
medication. New technologies based on the inhibition of
a speciﬁc gene involved in the development of thyroid
tumour may be used to avoid or to lower the secondary
eﬀects of these treatments. They could also be used in the
cases of resistance. Since ret/PTC1 plays a crucial role in
the early stage of the tumour development (24), and is
only present in the tumour cells, it appears to be a very
good target for RNA interference based-treatment. This
process consists in sequence-speciﬁc down-regulation
by the use of short, double stranded RNAs named short
interfering RNAs (siRNA). These siRNA are incorpo-
rated into a RNA-induced silencing complex (RISC) and
serve as a template for sequence speciﬁc cleavage by RISC
of the targeted mRNA. Cellular exonuclease activity
induces complete degradation of the mRNA (25).
Such strategies have already been used for speciﬁc
targeting and down-regulation of fusion oncogenes in
chronic myeloid leukaemia and in a bone cancer, the
Ewing sarcoma (26,27). In this study we extended this
strategy to the human ret/PTC1 oncogene. For this
purpose, we introduced the oncogene into NIH/3T3
murine ﬁbroblast cells. These transformed cells were
then used as a cellular model for in vitro and in vivo
experiments. The importance of the ret/PTC1 gene in the
cell transformed phenotype was then tested in order to
establish if it constitutes a major target whose artiﬁcial
blockage would result in an anticancer eﬀect. In this view,
we identiﬁed a sequence of siRNA, speciﬁc to the ret/
PTC1 junction and able to silence the ret/PTC1 oncogene
expression. Then ret/PTC1 silencing has been correlated
with the phenotypic reversion to NIH/3T3 wild-type cells.
This siRNA sequence can work as synthetic siRNA as well
as a shRNA construction. As a ﬁrst trial of the nano-
particles vector, we chose a intra-tumoral protocole.
In vivo studies have conﬁrmed the relevance of using
chitosan-coated poly(isobutylcyanoacrylate) nanoparticles
as a delivery system to inhibit the expression of ret/PTC1
as a treatment of the papillary thyroid carcinoma.
MATERIALS AND METHODS
Nucleic acids
The ret/PTC1 coding sequence cloned in a pBABE-puro
plasmid containing the RET/PTC1 cDNA under the LTL
promotor was kindly provided by Dr A. Fusco (University
Federico II, Naples, Italy). Target sequences of siRNAs,
named 1, 2, 3, 4 and 5, respectively, correspond to the
human ret/H4 junction mRNA as indicated on the
Figure 1. Speciﬁcity was tested using the BLAST search
engine (www.ncbi.nlm.gov/BLAST), and excluding ortho-
logous indentity, no siRNA had matches of more than
13 nucleotides to known human or murine mRNAs,
or expressed sequence tags. RNAs were chemically syn-
thesized and PAGE puriﬁed by Eurogentec (Belgium).
20-Deoxynucleotides residues were used as the 30 over-
hangs in the both sense and antisense strands so that
it matched with mRNA sequences. Duplex formation
was obtained by the preparation of 20mM of sense and
antisense RNAs aliquots in annealing buﬀer (Eurogentec)
and then heating at 908C for 1min followed by a further
incubation at 378C for 1h; aliquots were stored at  208C.
An irrelevant sequence duplex siRNA was used as a
control in the experiments. It was prepared from the RNA
sequences given in Figure 1 according to the same
procedure as described above.
Cell cultureand transformation protocol
The NIH/3T3 cells were grown in DMEM medium
(Gibco) containing 10% newborn calf serum inactivated
by heat (Gibco) and a blend of antibiotics (100U/ml
penicillin, 100mg/ml streptomycin, Gibco) at 378C, 5%
CO2, in a moist atmosphere.
For plasmid transfection experiments, 10
6 cells were
plated in a 100mm dish. The plasmid was transfected
into the cells with Superfect agent (Qiagen) as following.
In a polystyrene tube, 1mg of plasmid was diluted in 100ml
of 10mM Hepes buﬀer pH 7.3, 100mM NaCl. Then,
2ml of Superfect (Qiagen) diluted in 100ml of the same
Hepes–NaCl buﬀer was added. After gently stirring, the
mixture was incubated for 10min at room temperature
for complexes formation. Fresh medium was added to
the cells and then, the 200ml of DNA-Superfect dilution
was then added to the cells in a fresh medium. After 48h
incubation, the medium was discarded and fresh
medium containing selection agent was added for further
time. Ret/PTC1 expressing cells where selected by adding
5mg/ml puromycine (Sigma), and shRNA expressing cells
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shRNA expression vector construction
We have cloned the sequence corresponding to the
most eﬃcient siRNA, the sequence designed as siRNA1,
and the control sequence, designed as siRNA Ct, into the
pTer plasmide (kindly provided by M. Kress, A Lwoﬀ
institute, Villejuif, France). The oligonucleotides con-
tained a sense target sequence, a microRNA-based loop
sequence of nine bases, and a antisense sequence, a
termination sequence for polymerase III of ﬁve thymidines
and appropriate ends for restriction enzymes in both
ends. Thus, the resulting sequences for sequence shRNA1
and sequence shRNACt hairpins are:
50-GATCCCCGTTACCATCGAGGATCCATTCAAGA
GATGGATCCTCGATGGTAACGTTTTTGGAAA-30
as sequence shRNA1 sense
50-AGCTTTTCCAAAAACGTTACCATCGAGGATCC
ATCTCTTGAATGGATCCTCGATGGTAACGGG-30
as sequence shRNA1 antisense
50-GATCCCGCCAGTGTCACCGTCAAGGTTCAAG
AGACCTTGACGGTGACACTGGCTTTTTGGAAA-30
as sequence negative control shRNA sense
50-AGCTTTTCCAAAAAGCCAGTGTCACCGTCAAG
GTCTCTTGAACCTTGACGGTGACACTGGCGG-30
as sequence negative control shRNA antisense (see
Figure 1C).
Duplexes where formed by heating 5min at 958C the
complementary sequence in annealing buﬀer (50mM Tris,
pH 7.5, 100mM NaCl in MilliQ water). The mixture
was cooled at 708C for 10min before allowing it to return
at room temperature. The duplexes were then phosphoryl-
ated by T4 Poly Nucleotide Kinase (New England
Biolabs) using the shipper protocol. After linearization
of the pTer plasmid by BglII and HindIII restriction
enzymes, the shRNA sequence was cloned, giving two
plasmids pTer-shCt and pTer-sh1.
siRNA treatment
The eﬀect of siRNAs was measured after cell transfection
with Cytofectin GSV (GTS). Pratically, 2 10
5 cells/well
were seeded in 35mm tissues culture dishes. Then, three
successive transfections were done at the time 8h, 24h and
48h. The transfection solution was prepared as following:
0.05nmol of siRNA were diluted in 50ml of a solution
containing 100mM NaCl, 10mM Hepes buﬀer pH 7.3.
A volume corresponding to 2mg of Cytofectine (GSV)
was then diluted in 50ml of 100mM NaCl, 10mM Hepes
buﬀer pH 7.3 and then added to the siRNA solution. The
complexes formation was obtained after 10min incuba-
tion at room temperature and gently mixing. The com-
plexes were then dropped on the cells in a fresh culture
medium containing serum.
Detectionof RET/PTC1 mRNA expression by RT-PCR
The mRNA extraction was performed with the TRIzol
reagent (Invitrogen) as indicated by the shipper from
the cells of each well. After concentration determination
and good quality control, 1mg of total RNA from treated
or control cells were incubated in 20ml ﬁnal volume of
M-MuLV RT (promega, France) for 1h at 428C. Then
ret/PTC1 mRNA expression was determined by PCR on
2ml of the reverse transcription product in 50ml ﬁnal
volume with Taq polymerase (Biolabs). The following
primers were used for ret/PTC1 ampliﬁcation (290bp):
forward 50-AGATAGAGCTGGAGACCTAC-30 and
reverse 50 CTGCTTCAGGACGTTGAA 30; for
GAPDH (531bp): 50 GACAACTCACTCAAGATTGT
CAG 30 and 50 CATTGTCATACCAGGAAATG 30. The
PCR product of ret/PTC1 and GAPDH were observed
at 290bp after 35 cycles and 531bp after 32 cycles,
respectively. PCR products were analysed on a 2%
agarose gel TAE [0.5 ] under 8.3V/cm The fragment
was observed under UV after staining with ethidium
bromide 0.5mg/ml. A 100bp ladder (New England
Biolabs) was used as a standard.
Real-time quantitative PCR
Cells were lysed using TRIzol reagent (Invitrogen, France)
and total RNA was recovered according to the manu-
facturer instructions.
The tumour extraction was performed as following. The
subcutaneous tumours were sampled and immediately
freeze in liquid nitrogen. The tumour were then crushed
in TRIzol reagent (Invitrogen, France) in a FastPrep 24
(MP Biomedicals) and the RNA was recovered according
to the manufacturer instruction. The RNA was then
incubated in a DNase, RNase free medium for 1h.
A 
          --CTGCGCAAAGCCAGCGTTACCATCGAGGATCCAAAGTGGGAATTCCCT-- 
 
siRNA  #1          CGUUACCAUCGAGGAUCCAdAdA 
siRNA #2               UUACCAUCGAGGAUCCAAAdGdT 
siRNA  #3     UACCAUCGAGGAUCCAAAGdTdG 
siRNA #4            GUUACCAUCGAGGAUCCAAdAdG 
siRNA #5     GCCAGCGUUACCAUCGAGGdAdT 
B 
 
siRNA #5  5′ – GCCAGCGUUACCAUCGAGGdAdT – 3′ 
        3 ′ – dTdTCGGUCGCAAUGGUAGCUCC – 5′ 
siRNA Ct  5′ – GCCAGUGUCACCGUCAAGGdAdG – 3′ 
        3 ′ – dTdTCGGUCACAGUGGCAGUUCC – 5′ 
C Structure of shRNA1 : 
 
GATCCCCGTTACCATCGAGGATCCATTCAAGAGATGGATCCTCGATGGTAACGTTTTTGGAAA-- 
  --GGGCAATGGTAGCTCCTAGGTAAGTTCTCTACCTAGGAGCTACCATTGCAAAAACCTTTTCGA
Structure of negative control shRNA :
GATCCCGCCAGTGTCACCGTCAAGGTTCAAGAGACCTTGACGGTGACACTGGCTTTTTGGAAA--
  --GGCGGTCACAGTGGCAGTTCCAAGTTCTCTGGAACTGCCACTGTGACCGAAAAACCTTTTCGA
ret  H4 
GCAAUGGUAGCUCCUAGGU 
CGUUACCAUCGAGGAUCCA  
A  A  G  U 
U 
C  U  C  U 
CGGTCACAGTGGCAGTTCC 
GCCAGTGTCACCGTCAAGG  
A  A G  U 
U 
C  U  C  U 
Figure 1. (A) Design of ret/PTC1 small interfering RNAs (siRNAs).
Location of ret/PTC1 sense sequence of siRNA nos 1, 2, 3, 4 and 5
examined in this study are shown under the junction sequence of
ret/PTC1. The H4 part of the oncogene is presented on the right
part (g). (B) The control sequence is the sequence #5 with four
mismatches. Mismatch site is shown in boxes. (C) Structure of the
shRNA1 and negative control shRNA.
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photometer (Nanodrop). Superscript II Reverse
Transcriptase kit (Invitrogen) was used for reverse
transcription. The same primers as for RT-PCR were
used for the ampliﬁcation of ret/PTC1. Taq Universal
PCR Master Mix (Applera) was used as ﬂuorescent dye.
Samples were ampliﬁed for 50 PCR cycles with continuous
monitoring of ﬂuorescence. 18S gene was used as a PCR
control using Human 18S rRNA MGB kit (Applera). The
Ct of the genes are respectively between 12 and 16 for 18S,
and between 20 and 27 for ret/PTC1. The ampliﬁcation
was monitored on an ABI prism 7700 real-time PCR
apparatus (Perkin–Elmer).
Proteinstudies
Immunoblotting experiments were performed according
to standard procedures. Brieﬂy, cells were harvested in
lysis buﬀer (RIPA solution) containing Tris 50mM, NaCl
150mM, EDTA 1mM glycerol 10%, NP 40 0.5% and
complete protease inhibitor (Roche, Germany). Protein
concentration was determined using BCA protein assay
(Pierce). After transfer on BAF-83 nitro cellulose
(Schleicher & Schuell) protein were detected with speciﬁc
antigens. Detection was performed by chemiluminescence
kit (ECL, Amersham). Anti-ret (C-term) antibodies were
from Abgent, and anti-actin were from Santa Cruz
Biotechnology.
Cytochemistry of stressfibre
The cells were plated at a concentration of 1.5 10
5 cells/
well in 6-well plates containing a cover glass. After 3 days
of treatment as previously described, the medium was
removed and the cells were washed with PBS, and then
ﬁxed with formaldehyde 4% in PBS for 20min at 48C.
The formaldehyde was then neutralized by a solution of
50mM NH4Cl in PBS before treatment with 0.4% Triton
X100 in PBS. RNA were discarded by 30min treatment
with 10mg/ml RNase A in PBS at room temperature.
The cover glass was then stained with 600 nM DAPI and
40 U/ml of FITC-conjugated phalloidin in PBS buﬀer.
The slides were observed with a microscope Nikon eclipse
E600 equipped with CCD camera.
Synthesis of nanoparticles by redoxradical emulsion
polymerization
Chitosan was hydrolysed as indicated by Bertholon et al.
(28), to reach a ﬁnal molecular weight of 20kDa. Chitosan
(0.137g) was dissolved in 8ml of 0.2M nitric acid aqueous
solution. After 10min at 408C under argon bubbling,
0.3g of Lutrol F68 (BASF) was dissolved in the solu-
tion, followed by the addition of 2ml of 80mM
Ce(NH3)2(NO3)4 in 0.2M HNO3 and 0.5ml of isobutyl-
cyanoacrylate (kindly provided by Henkel Biomedical)
under vigorous stirring. Polymerization was performed
under vigorous stirring for 50min. Gentle argon bubbling
was maintained during the ﬁrst 10min. Then, the reaction
medium was cooled at 158C and pH was increased until
6.0. Nanoparticles were puriﬁed by dialysis against MilliQ
water (MWCO: 100000; 2 1l, 2h and 1l overnight),
providing a slightly turbid solution.
Nanoparticles characterization
Particle size. The hydrodynamic diameter of the nano-
particles was measured at 208C by quasi-elastic light
scattering using a Nanosizer N4 PLUS (Beckman-Coulter,
France), operating at 908. Sixty microlitres of each sample
was diluted in 2ml of MilliQ water. The temperature
was allowed to equilibrate 5min before measurement. The
results gave the mean hydrodynamic diameter of the
dispersed particles obtained from three independent
determinations. The standard deviation of the size
distribution and the polydispersity index were also given.
Zeta potential. A good estimation of the surface charge
of the particles is the measure of their zeta potential.
It was measured using a Zetasizer 4 (Malvern Instrument
Ltd, France). Dilution of the suspensions [1:33 (v/v)] was
performed in NaCl 1mM.
Transmission electron microscopy. Transmission electron
microscopy (TEM) was performed using a Philips EM208
with a large format CCD camera AMT at the CCME
Orsay. The samples were diluted in MilliQ water 1:100 and
deposited on a carbon-coated formwar ﬁlm on copper
grids. After 5min, the excess was removed and stained with
neutral 1% aqueous phosphotungstic acid during 30s.
Preparation of
32P-labelled siRNA
SiRNA #1 were labelled at the 50-end by T4 polynucleo-
tide kinase (New England Biolabs) and [g-
32P]ATP
(Amersham Bioscience) in 50ml of reaction mixture.
Thus, 5ml of siRNA #1 stock solution (20mM), RNase-
free water (30ml), 10  kinase buﬀer (5ml; New England
Biolabs), 5ml of T4 polynucleotide kinase (10U/ml),
and 5mlo f[ g-
32P]ATP (>5000Ci/mmol) were incubated
at 378C for 1h, and 20min at 658C. The reaction mixture
was placed in the upper chamber of MicroCon YM3
(cutoﬀ value Mr 3000; Millipore). After adding 200ml
of RNase-free water, it was centrifuged (4000g). The
procedure was repeated four times. Material remaining
in the upper chamber was regarded as g-
32P-labelled
siRNA #1.
siRNA adsorption on nanoparticles
Nanoparticle (NP) suspensions were diluted in MilliQ
water at diﬀerent concentrations to reach the following
mass ratios nanoparticles/siRNA (0; 10; 20; 25; 30; 40;
45; 50; 100 and 300). The
32P-labelled siRNA was added
to each nanoparticle suspension to reach a ﬁnal siRNA
concentration of 0.5mM in a ﬁnal volume of 300ml.
Liquid paraﬃn was then added to equilibrate the tubes
for ultracentrifugation. After 10min of incubation, the
suspension was ultracentrifuged in a 70.1 Ti rotor at
45000rpm (average g-force: 138915) at 48C for 1h. The
radioactivity of 100ml of supernatant was measured for
non-adsorbed siRNA quantiﬁcation.
PAGE anlaysis ofc-
32P-labelled siRNA injected into
the tumour
g-
32P-labelled siRNA associated with nanoparticles was
injected into RP1 tumours. After 24h and 48h of
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0.5ml of ice cold Tris–HCl (pH 8.0) with 0.1% Triton X-
100, 50mM NaCl, and RNase inhibitor (1U/ml, Roche)
and then centrifuged. Proteinase K (1mg; Roche) was
directly added to the supernatant and incubated for 6h at
378C and centrifuged (1000g; 10min). The supernatant
was analysed by PAGE (10% gel) followed by
autoradiography.
Animal experiment
All animal experiments were carried out according to the
French Laws of animal welfare and were approved by the
Ethics Commission of the oﬃcial veterinary authorities.
The tumorigenicity tests were performed on nude mice
product by the laboratory. The mice were pre-irradiated
by 5Gy 1day before tumour implant. 10
6 living cells were
injected subcutaneously into the right ﬂank of nude mice.
The tumour sizes determination was performed with by
a digital slide caliper, and the tumour volume in cubic
millimetres was calculated by the formula: volume=
(width)
2 length/2. Data are presented as mean SE.
After 1 week, when the tumours reached a volume
of  50mm
3, the tumour bearing nude mice were treated
with siRNA #1 and siRNA Ct. Four micrograms of
siRNA complexed with, or without, 200mg of nanopar-
ticles were diluted in 100ml 0.9% saline before injection.
As positive control, physiological serum or nanoparticles
diluted in physiological serum were injected. Each
therapeutic reagent was injected into the tumour every
2 days after the ﬁrst injection, as indicated in Figure 6B.
A ﬁnal volume of 100ml was intratumoral injected.
RESULTS
Nanoparticles characterization
As shown by Bertholon et al. (28) the size of the ﬁnal
nanoparticles is tightly related to the molecular weight
of the chitosan used during the polymerisation process.
Hydrolysis of the commercial chitosan up to a 20kDa
molecular weight decreased the size of the nanoparticles
to 178nm. The use of a surfactant allowed to dramatically
decrease the size of the obtained nanoparticles. Indeed,
the addition of Lutrol F68 reduced the hydrodynamic
diameter of the nanoparticles from 107nm with 1% (m/v)
to 41nm with 4% (m/v) (Figure 2A). These results were
consistent with the observed reduction of the solution
turbidity. No reduction was obtained by addition of the
lutrol 68 after the polymerisation. The size reduction
is due to a nanoparticle core size reduction, not to a
collapse of the chitosan brush (data not shown). Until
now, it was only possible to prepare nanoparticles with
size over 200nm (29), thus reducing size is new. This is
an important fact as too big nanoparticles cannot enter
cells eﬃciently and too small particles cannot remain and
accumulate in the tumours after translocation through
the wide fenestration of the tumour endothelium (the
so-called ‘Enhanced Permeability and Retention Eﬀect’)
(29). We have thus chosen to use medium sized nano-
particles of 60nm (i.e. 3% Lutrol F68) for the in vivo
study, that can penetrate cells and accumulate.
As shown in Figure 2B, these nanoparticles appeared
round-shaped at TEM with a size of  30nm and they did
not aggregate. Since drying of the sample was needed
before TEM observation, the chitosan brush, naturally
expanded in water, was completely folded up on the
polymeric surface. This explains the observed lower size
at TEM (30nm) comparatively to the 60nm measured
by quasi-elastic light scattering, since the hydrodynamic
diameter take into account the thickness of the chitosan
brush too.
These nanoparticles displayed a positive value of the
zeta potential (+26mV) due to the chitosan surface
(Figure 2E, ratio siRNA/nanoparticles=0) which insured
an excellent colloidal stability to the suspension. No
change in the zeta potential nor in the size of nanoparticles
was observed after 10 months conservation at 48C. A light
white deposit was observed that could be resuspended by
gentle agitation.
Adsorption of thesiRNA on thenanoparticle surface
When mixing positively charged chitosan-decorated nano-
particles with negatively charged siRNA, nanoplexes
could be obtained (Figure 2C). For a ratio nanoparti-
cles/si RNA of 50, siRNA adsorption onto nanoparticles
reached  90% (Figure 2D). Noteworthy, no modiﬁcation
of the adsorption isotherm was observed when a 10-month
old nanoparticle preparation was used, conﬁrming the
high stability of the nanoparticles suspension.
The adsorption of siRNA onto the nanoparticles
surface was further investigated by measuring the zeta
potential of the particles according to the addition of
increasing amount of siRNA (Figure 2E). As expected,
siRNA adsorption induced a negative zeta potential value
of the nanoplex, and the more siRNA was added, the
more the zeta potential was negative. The mass ratio 1/50
(siRNA/nanoparticles) led to a resulting zeta potential of
 11.8mV. No signiﬁcant modiﬁcation of the nanoparticle
size was observed after siRNA complexation.
Tumoraltransformation ofthe cells
NIH/3T3 cells were stably transfected by the ret/PTC1
expression plasmid, giving the RP1 cell line. The ret/PTC1
mRNA expression was determined on the RP1 cell line
and was associated to some morphological modiﬁcations
(Figure 3).
NIH/3T3 murine ﬁbroblasts were characterized by
a monolayer growing with a ﬂat aspect and generally
possessing four angular extremities. The introduction of
the ret/PTC1 oncogene into NIH/3T3 cells changed their
morphology with a difringent round aspect with two
extremities (Figure 3A).
The shape modiﬁcation is a marker of deep cytoskele-
ton reorganization. The NIH/3T3 ﬁbroblasts have a ﬂat
aspect associated to a well-organized actin ﬁbre. The
round refringent aspect of the RP1 cell line is associated
to a loss of these actin ﬁbres with an homogenous green
colored cytoplasm (Figure 3B).
We observed that the parent NIH/3T3 cells grew as
a mono-layer and stopped dividing when conﬂuence
occurred. In the case of RP1 cells, they go one over the
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inhibition. This ability to grow without support attach-
ment resulted in big ﬂoating aggregates. This is typical of
a tumorigenic transformation of the cells. As it is shown
on the Figure 3C, the RP1 cells formed aggregates even
without monolayer of cells. This result pleads in favour
of a cell chemioattraction. Moreover growth continued
after conﬂuence as observed by the MTT test (data not
shown).
Screeningof the ret/PTC1 siRNA sequencesin cells
As presented in Figure 4B, we compared the diﬀerent
siRNAs of Figure 1, targeted on the oncogene junc-
tion area. Using similar experimental conditions for all
siRNAs, the number one was found to be the most
eﬃcient after RT-PCR quantiﬁcation of ret/PTC1 express-
ion inhibition. Thus, siRNA #1 was chosen for further
experiments. Control siRNA showed no eﬀects. The
Q-PCR analysis revealed an 89% ret/PTC1 mRNA
inhibition for treated cells compared to untreated RPI
cells (Figure 4C). Western blot analysis conﬁrmed the
down-regulation of the ret/PTC1 oncoprotein by trans-
fection of the siRNA. It can be seen in Figure 4D that the
two bands of 64kDa and 59kDa corresponding to the
two isoforms of the ret/PTC1 oncoprotein were down-
regulated. We also investigated the reorganization of the
actin stress ﬁbres as a phenotypical reversion associated
with the down-regulation of ret/PTC1. RP1 cells receiving
control siRNA still lack stress ﬁbres in the cytoplasm.
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the cytoplasm, conﬁrming the reorganization of actin in
ﬁbres, as observed in NIH/3T3 mother cells (Figure 4E).
Transfection of RP1 cells with the ﬂuorescent siRNA #1
gave a characteristic spotty distribution of ﬂuorescence
around the nuclei (Figure 4A).This is consistent with an
uptake of the siRNAs after transfection.
In vitro effectof theshRNA expression plasmid
To overcome the poor in vivo stability of siRNA, we then
shifted to the shRNA strategy containing a H1 promotor.
RP1 Cells were transfected and selected in medium con-
taining zeocin. After selection, individual colonies were
isolated and the knockdown of the ret/PTC1 oncogene
was tested by RT-PCR. Two clones of pTer-sh1 trans-
formed cells were selected with two diﬀerent levels
of ret/PTC1 inhibition. The cells expressing the control
shRNA gave no diﬀerence compared to mother cells RP1.
Aggregates could still be observed, and the cells remained
to have a round shape. On the contrary, cells expressing
the antisense shRNA, returned to have contact inhibition,
no aggregates were visible, and the cells had a ﬂattened
form. Q-PCR evaluation conﬁrmed the ability of pTer-sh1
to inhibit the ret/PTC1 oncogene. Two clones resisting
to zeocin, (sh1-11 and sh1-19) were selected with two
diﬀerent levels of ret/PTC1. sh1-11 and sh1-19 have a
residual ret/PTC1 expression of, respectively 4% and
36%, in comparison with RP1 mother cells (Figure 5A).
The expression vector of the shRNA control, pTer-shCt,
was unable to down-regulate the ret/PTC1 oncogene in
RP1 cells. One clone resisting to zeocin, shCt was selected
as control clone. Q-PCR revealed an expression rate
of ret/PTC1 of 93% (Figure 5A). These results were
conﬁrmed by western blot analysis on the three clones
(Figure 5B). Finally inhibition of ret/PTC1 in RP1 cells
by pTer-sh1 plasmid induced actin ﬁbre reorganization
whereas no actin ﬁbres were observed with the pTer-shCt.
A
B
C
NIH/3T3 RP1
Figure 3. Phenotypicals features of the NIH/3T3 cells and of the ret/PTC1 transformed NIH/3T3 cells, named RP1. (A) Not conﬂuent cells
(phase contrast). (B) Cytochemistry coloration of actin ﬁbres (falloidine-FITC and DAPI coloration). (C) Conﬂuent cells (phase contrast).
PAGE 7 OF 13 Nucleic Acids Research, 2008, Vol. 36,No. 1 e2It was interesting to observe that low inhibition of the
ret/PTC1 was not able to reverse the phenotype as for
sh1-19 whereas an important inhibition of the oncogene,
as observed in sh1-11, was able to completely reverse
phenotypic inhibition (Figure 5C).
Invivo tumorigenic effect ofshRNA pretreated RP1cells
After subcutaneous injection of 10
6 living cells from
each clone into the ﬂank of irradiated nude mice, tumours
became visible on the RP1 injected group (n=30). The
tumoral growth was then followed during 17 days. The
results are given on Figure 6A where it can be seen
that after 17 days, the RP1 cells and the shCt reached
a volume of 4000 cm
3, whereas the sh1-19 cells reached
only 263 cm
3 and no tumour growth was visible for the
NIH/3T3 and the sh1-11 treated animals. Post-mortem
analysis revealed no tumour nodule peripheral organ.
A light increase in the volume of the spleen was just
observed. The tumoral growth was then related to the
expression of ret/PTC1 in NIH/3T3 cells. No loss of body
weight was observed during the experimental period (data
not shown).
In vivo treatment of a RP1 derived tumour by
ret/PTC1 siRNA
Fifteen days after subcutaneous injection of RP1 cells
(1.0 10
6) into the ﬂank of irradiated nude mice, tumour
nodules were observed (mean tumour volume: 43.35mm
3;
n=30). For the determination of the therapeutic eﬀect
of ret/PTC1 siRNA, intratumoral injections of siRNA
loaded onto nanoparticles or nanoparticles alone were
started and repeated for a total dose of siRNA of 1mg/kg
in ﬁve injections. As a ﬁrst trial with the new siRNA, we
have chosen to perform intra-tumoral injections instead
of systemic injections. In fact, by using systemic injection,
the uncertainty about the bio-distribution of a new
formulation can be an additional obstacle compromising
the initial in vivo evaluation of the drug cellular eﬃciency.
The tumour delivery eﬃciency of the new formulation is
one of our goals. This choice was also based from our
previous experience on the Ewing Sarcoma (27).
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Figure 4. Analysis of the inhibition of ret/PTC1 by cytofectine transfected siRNA in vitro.( A) Penetration of the Rhodamine-labelled siRNA into
RP1 with cytofectine. (B) Eﬀect of siRNA target sequence on ret/PTC1 expression by RT-PCR. The siRNA were transfected by cytofectin GSV with
a ﬁnal concentration of 50nM. (C) Q-PCR and (D) western blot analysis of the most eﬃcient siRNA #1 transfected by cytofectin. (E) Cytochemistry
of stress ﬁbres in RPI cells transfected with control siRNA (Ctrl) or antisense siRNA #1. Three siRNA transfections were performed before analysis.
  P<0.001 versus RP1.
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complexed with the nanoparticles signiﬁcantly inhibited
tumour growth as compared to ret/PTC1 siRNA free,
to siRNA control (complexed or not with nanospheres)
or to nanoparticles alone (P<0.05). Q-PCR analysis
of the tumoral mRNA reveals a high down-regulation of
the expression of ret/PTC1 gene after siRNA #1/
nanoparticle treatment. No signiﬁcant inhibition of the
gene was observed after control siRNA treatment
associated with nanoparticles or by free nanoparticles
(Figure 6C).
50-Radiolabelling of the siRNA by a Poly Nucleotid
kinase allowed us to detect its intact form 48h post
injection. At this time a signiﬁcant amount of radiola-
belled siRNA remains intact in the tumour after
nanoparticules association whereas the intact form is no
more observable without nanoparticles complexation
(Figure 6D).
Statistical analysis
GraphPad Instat software was used for the statistical
analysis. The ANOVA test was performed.
A
B
3T3
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shCt
sh1_19
Sh1_11
Ret/PTC1
actine
C
05 0 1 0 0
3T3
RP1
shCt
sh1-11
sh1-19
Ret/PTC1 mRNA (% of untreated cells)
shCt Sh1_11
Sh1_19
*
*
*
Figure 5. In vitro shRNA inhibition of ret/PTC1. (A) and (B) Q-PCR and western blot analysis of the clones expressing the shRNA. ShCt expresses
the negative control sequence, sh1_11 and sh1_19 express the speciﬁc shRNA at various levels. (C) Cytochemistry of stress ﬁbres in clones expressing
the shRNA.
 P<0.05 and
  P<0.001 versus RP1.
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Many researchers consider siRNAs as promising ther-
apeutic agents. However, RNA is a fragile molecule which
is degraded in biological ﬂuids and poorly diﬀuses through
the cell membrane. This is the reason why non viral
vectors are needed to allow their eﬃcient delivery in vivo.
However, in view of their possible use in clinic, artiﬁcial
carriers require to be biocompatible and well character-
ized. This is the reason why we propose, in the present
article, to use chitosan-coated biodegradable poly(iso-
butylcyanoacrylate) nanoparticles for the administration
of a siRNA oriented towards the junction oncogene in the
papillary thyroid carcinoma. This carcinoma is mainly due
to a paracentric inversion of the chromosome 10. This
leads to the fusion of the 50 sequence of ret with the 30 part
of an ubiquitously expressed gene, H4. As a result, the
gene under the H4 promotor, is abnormally expressed in
follicular cells and the chimerical protein is re-localized in
the cytoplasm compartment and constitutively activated
(20). To develop a new strategy based on gene inhibition
it was important to control whether the modulation
of ret/PTC1 expression was or was not associated with
the tumorigenicity of thyroid carcinoma cells. For this
purpose, we used a model of tumour cell obtained by
the introduction of this human oncogene into murine
ﬁbroblasts NIH/3T3. We observed that the expression
of the ret/PTC1 gene was suﬃcient to transform the
NIH/3T3 cells from immortal and not tumoral to tumoral.
Noteworthy non transformed NIH/3T3 cells were unable
to form tumor after grafting in nude mice, conﬁrming
the absence of transformation of the commercial cell line.
The ret/PTC1 transformed NIH/3T3 cell line reversibly
became spindle-shaped or round as was already observed
by others (30). Such shape transformation is the con-
sequence of cytoskeleton reorganization. Indeed, it is
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Figure 6. In vivo studies. (A) Tumoral growth of the diﬀerent shRNA clones after grafting on the right ﬂanc.
  P<0.001 versus RP1. (B) Antitumor
eﬀect of the ret/PTC1 small interfering RNA (siRNA) in the RP1 graft. Injections were performed on days 0, 2, 4, 7, 10 as indicated by the arrows.
siRNA were dissolved in 0.9% NaCl. The following preparations were intratumorally injected: free siRNA #1 (siRNA #1), free control siRNA (Ctrl
siRNA), unloaded nanoparticles (free NP), siRNA #1 associated with nanoparticles (siRNA #1/NP) and control siRNA associated with
nanoparticles (Ctrl siRNA/NP).
 P<0.05 versus 0.9% NaCl-treated mice. (C) Q-PCR analysis of the ret/PTC1 expression in tumor tissues at day 11
after the ﬁrst injection. (D) stability of nanoparticles-associated
32P-labelled siRNA and free
32P-labelled siRNA after intratumoral injection. The
total RNA was extracted from tumor and analysed by PAGE as described in materials and methods. Experiments start at the ﬁrst injection.
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stress ﬁbres (31). We have conﬁrmed these data, but in
addition, we have shown that expression of ret/PTC1
in these cells induced a complete disorganization of actin
ﬁbres (Figure 3B). This eﬀect seemed to be related to cells
that have naturally stress ﬁbres, such as NIH/3T3 trans-
formed cells. In fact, ret/PTC1 expression induced actin
organization in stress ﬁbres in PC Cl 3 rat thyroid cells,
that naturally lack actin stress ﬁbres (32). Barone et al.
explained this result by the fact that ret/PTC1 signaliza-
tion pathways diﬀer in thyroid cells and ﬁbroblasts.
In fact, the chimerical protein ret/PTC1 activates
BRAF through Grb2/SOS>RAS pathway and Grb2/
Gab1>Rap1 pathway (33). In PC Cl 3 cells, Rho
activation through Rap1 induces actin stress ﬁbres
formation (32,34). On the contrary, in the NIH/3T3
model used here, the Phosphoinositide 3-OH Kinase and
Ras, both activated by ret/PTC1 (20,35), induced actin
stress ﬁbres disorganization and morphological changes
via ERK (31). The NIH/3T3 cell model is nevertheless
an interesting model to test the eﬃciency of artiﬁcial
ret/PTC1 down-regulation because of its strict ret/PTC1
phenotype dependency. For a pharmacological approach,
we have made the choice of the siRNAs as potential
therapeutic molecules. Before undertaking expensive
in vivo experiments it was necessary to check the validity
of ret/PTC1 as a relevant antitumor target. The shRNA
strategy oﬀers the advantage of long term inhibition of
the studied gene and greatly facilitates the in vivo esti-
mation of the target validity. Using the siRNA sequence
selected as the most eﬃcient one to inhibit ret/PTC1 we
have integrated it in a plasmid construction and shown
that the selected cells displayed a permanent inhibition
of ret/PTC1 (96% inhibition for the shRNA in sh1-11
clone). We found that inhibition of the ret/PTC1 oncogene
by shRNA was able to completely reverse the RP1
phenotype in culture. In order to obtain a better relation-
ship between oncogene inhibition and phenotype rever-
sion, we selected two clones with diﬀerent level of ret/
PTC1 down-regulation. The oncogene inhibition by the
shRNA in sh1-19 clone provided a lower inhibition than
in sh1-11 clone with 36% of ret/PTC1 expression left
instead of 4%. The diﬀerent levels of inhibition by the
shRNA into the cells can be explained by the clone
selection. Selected clones have, indeed, chromosomal
integration of the transfected plasmid. As a result, the
shRNA concentration in the cytoplasm will depend on
integration regions and will be variable. Accordingly, we
have found that the inhibition of ret/PTC1 by shRNA was
dependent on the selected clone. The protein analysis by
western blot has conﬁrmed these results. Further in vivo
studies have demonstrated ret/PTC1 oncogene silencing.
No silencing or low silencing (less than 64% silencing)
induced tumor growth but 90% silencing resulted in
tumoral growth inhibition. As a conclusion, antitumoral
eﬀect by silencing the oncogene needs a very high level
of inhibition.
Although powerful, the shRNA strategy requires the
selection of clones which might not be representative of
the whole cell population. Therefore, it was necessary
to directly evaluate the eﬀect of siRNAs on the RP1
phenotype, This could be obtained after 3 transfections,
without any sign of cytotoxicity regarding MTT assays
(data not shown); additionally, no actin stress ﬁbres
modiﬁcation was observed after transfection of the control
siRNA using cytofectine. By applying the same transfec-
tion protocol for the siRNAs, 89% inhibition of ret/PTC1
could be obtained in vitro for several days. Despite such
high ret/PTC1 inhibition, measured by PCR and western
blot, the actin skeleton of individual cells did not appear
to be homogeneous. Only a signiﬁcant population of cells
had complete phenotypic reversion whereas few cells did
not have complete actin stress ﬁbres reorganization. These
data highlight the problem of the individual cell trans-
fection heterogeneity. Nevertheless, the phenotypic rever-
sion was very similar to that obtained with the shRNA.
The validity of ret/PTC1 as an antitumor target was
therefore, demonstrated. It was also demonstrated that
this characteristic of ret/PTC1 expression was not related
to the selection of a few clones. Further experiments were
also needed to check for an always possible additive oﬀ-
target eﬀect of our RET/PTC1 siRNA in the phenotypic
reversion of RP1 cells. However, the NIH/3T3-NIH/3T3
RP1 system where RP1 diﬀered initially from NIH/3T3
only by the RET/PTC1 protein expression argues for
a non necessary additional gene inhibition to the RET/
PTC1 inhibition in the phenotypic reversion. According
to our initial hypothesis targeting junction oncogenes,
rather than oncogenes, with punctual mutations or
modiﬁcations of their expression regulation should result
in a better speciﬁcity of the siRNA. In fact, the lack of
speciﬁcity is the main cause of side eﬀects in preclinical
trials (36). Taking into account the results described
above, oﬀ target eﬀects and speciﬁcity of siRNA target-
ing junction oncogenes could be evaluated in vivo using
nanoparticles.
For performing the in vivo experiments with RET/PTC1
siRNA, we have employed, for the reasons explained
before, the previously described chitosan/poly(isobutyl-
cyanoacrylate)core-shell nanoparticles prepared by radical
polymerization. Noteworthy, these nanoparticles were
never tested before in vivo. Since too big nanoparticles
cannot enter cells eﬃciently and too small particles cannot
accumulate into tumors (after diﬀusion through the more
permeable tumor endothelium), the control of the particle
size was needed. This has been done by using the FDA
approved surfactant, Lutrol F68. This original modiﬁca-
tion has led to nanoparticles with sizes of 60nm instead of
200nm as previously obtained without this surfactant.
In fact, the isobutyl monomer is not soluble in water and
will form a microemulsion during the energetic steering
of the reaction medium. At low pH, anionic initiation of
the polymerization is hindered. Only the cerium-induced
radical on chitosan can initiate the polymerization lead-
ing to chitosan-coated nanoparticles. The use of the
surfactant led to stabilize smaller size monomer drop-
lets in the medium, resulting in smaller nanoparticles.
Noteworthy, both poly(isobuthylcyanoacrylate) and chit-
osan were chosen because of their biocompatibility
(37,38). The tolerance of the nanoparticles in mice can
be conﬁrmed since there was no reduction of the mice
weight during the treatment. To our knowledge, the use
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macro-molecules was never done before. As they could
ensure the presence of the siRNA in its intact form more
than 2 days after intra-tumoral injection, these nano-
particles, associated with siRNA, were found to induce
a signiﬁcant inhibition of the tumor growth. Quantitative
PCR of the ret/PTC1 oncogene shows a down-regulation
of 82% of the ret/PTC1 oncogene in the tumor revealing
that the siRNA is delivered in an active form inside the
tumor. This result demonstrates the usefulness of these
core-shell type nanoparticles for in vivo siRNA delivery.
The mechanism needs to be explored. Indeed, the two
most probable explanations for the eﬃciency of the
method are either—an increase of the in vivo stability of
the siRNA associated with nanoparticles, or retention of
the siRNA inside the tumor. In this case, nanoparticles
would play a role of a ‘nanoimplant’ inside the tumor.
The in vivo eﬃciency comparison between free and vector-
ized stabilized siRNA (with O-methylation or LNA) could
answer this question. Both protection of the siRNA
and tumoral accumulation are the main goal for a vector
development. The systemic injection has to be explored,
as the intra-tumoral injection is only a preliminary investi-
gative treatment. Because the enhanced permeability and
retention eﬀect can result in a passive tumor targeting, this
treatment can be already used. Surface antibody grafting
can be a nice improvement of the method, as this would
allow having an active targeting.
Because of their dual composition, allowing to carry
nucleotides at the surface and more hydrophobic com-
pounds in the core, the nanoparticles described in this
article could be further tested in association with other
anticancer molecules.
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